ELAB vs TECH · rev $1.7M vs P/E 65, rev $1.22B
Elevai Labs, Inc. Common Stock (ELAB) versus Bio-Techne Corp (TECH) — a side-by-side from cached financials, not a winner call.
Elevai Labs, Inc. Common Stock (ELAB) is a biotechnology company listed on NASDAQ.
Bio-Techne Corp (TECH) is a biotechnology company listed on US.
Latest reported ELAB revenue for 2023-12-31 was $1.7M. Net income was -$4.3M. Revenue was up 123.5% from 2022-12-31 to 2023-12-31. ELAB currently screens at market cap $6.5M.
Latest reported TECH revenue for 2025-06-30 was $1.22B. Net income was $73.4M. Revenue was up 5.2% from 2024-06-30 to 2025-06-30. TECH currently screens at market cap $8.49B and trailing P/E 65.2.
ELAB currently screens at market cap $6.5M. TECH currently screens at market cap $8.49B and trailing P/E 65.2.
Not investment advice. Open the ELAB and TECH stock pages for the full models.
Not investment advice.